Han Teo Lee

Han Teo Lee

Auto-generated profile, based on publicly available information

Han Teo Lee

Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Lipid and Atherosclerosis
Verified
Journal Article
Open access
PDF file
HLHan-Teo Lee
Han-Teo Lee
SOSanghyeon Oh
Sanghyeon Oh
DRDu Hyun Ro
Du Hyun Ro
HYHyerin Yoo
Hyerin Yoo
YKYoo-Wook Kwon
Yoo-Wook Kwon
Lee HT, et al. J Lipid Atheroscler. 2020 Sep;9(3):419-434. https://doi.org/10.12997/jla.2020.9.3.419

10 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SAShandon M. Amos
Shandon M. Amos
CCChi-Chao Chen
Chi-Chao Chen
YXYichen Xiang
Yichen Xiang
KMKeisuke Motoyama
Keisuke Motoyama
TGTania J. González-Robles
Tania J. González-Robles
YSYadira M. Soto-Feliciano
Yadira M. Soto-Feliciano
Chromatin regulation critically influences gene expression and cancer progression, yet the functions of chromatin adaptors remain incompletely defined. Using focused CRISPR screening, we identified TRIM28, a multi-domain chromatin adaptor, as a dependency in acute leukemia, where its depletion impaired leukemia cell proliferation in vitro and in vivo , while activating neutrophil differentiation programs. Integrative transcriptomic and chromatin profiling revealed that TRIM28 acts as a co-repressor of neutrophil-associated loci independently of H3K9 methylation, and that TRIM28 loss drives terminal differentiation of leukemia cells into functionally mature neutrophil-like cells with reduced leukemic potential. We developed a selective small-molecule TRIM28 inhibitor that binds the TRIM28 PHD-bromodomain, phenocopies TRIM28 loss across biochemical and cellular assays, exhibits low micromolar anti-leukemia activity, induces neutrophil differentiation, and synergizes with Menin inhibition. Together, these findings, spanning target discovery, mechanism of action, and chemical probe development, establish TRIM28 as a regulator of myeloid cell fate and a promising pro-differentiation therapeutic target in acute leukemia.